Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIVAL: Aflibercept for Polypoidal Choroidal Vasculopathy
NCT02092532Phase 4Unknown
- Sponsor
- Southeast Retina Center
- Start
- Mar 2014
- Primary completion
- Mar 2015
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 4, open-label trial of aflibercept in polypoidal choroidal vasculopathy (PCV), sponsored by Southeast Retina Center. Primary endpoint: Incidence and Severity of Adverse Events at 12 months. Status: unknown.
02
Drugs
aflibercept
03
Conditions
polypoidal choroidal vasculopathy (PCV)
Beyond the preview
Go deeper on NCT02092532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02092532.